Univariate analysis of factors correlated with tumor control probability of three-dimensional conformal hypofractionated high-dose radiotherapy for small pulmonary or hepatic tumors.
case_series · Level IV
Where this comes from
- Record sourced from PubMed, PMID 15001252.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
To show the factors correlated with tumor control probability (TCP) after three-dimensional conformal hypofractionated high-dose radiotherapy (3D-CHHRT) for small pulmonary or hepatic tumors. We enrolled 34 patients with 42 lesions (13 lung carcinomas, 6 hepatocellular carcinomas, and 23 lung or liver metastases) treated with 3D-CHHRT alone, with simple immobilization devices, between July 1997 and January 2002. We prescribed 45 Gy in three fractions at the 90-100% isodose line of the planning target volume. The median follow-up period was 18 months (range, 4-46 months). We calculated the TCP using the Kaplan-Meier method and univariate analysis for the following factors: age, gender, primary site, histologic type, tumor size, and previous treatment. Overall, the 2-year TCP of 3D-CHHRT was 83.6%. Local recurrence was observed in 6 lesions within 1 year after treatment. We showed that tumor size was the only significant factor to correlate with the TCP in univariate analysis. The 2-year TCP for tumors <3 cm or > or =3 cm in diameter was 95.0% and 58.3%, respectively (p = 0.0022). No severe adverse effects were observed. The TCP for tumors <3 cm in diameter was excellent for 3D-CHHRT.
Medical subject headings
- Adenocarcinoma
- Carcinoma, Hepatocellular
- Carcinoma, Squamous Cell
- Liver Neoplasms
- Lung Neoplasms
- Radiotherapy, Conformal